[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pars-plana-vitrectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pars-plana-vitrectomy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100570432","intraocular-pressure-measurement-at-the-end-of-pars-plana-vitrectomy-100570432",false,"NCT06707168","INTRAOCULAR PRESSURE MEASUREMENT AT the END of PARS PLANA VITRECTOMY","ACCURACY of DIGITAL INTRAOCULAR PRESSURE MEASUREMENT AT the END of PARS PLANA VITRECTOMY SURGERY","Inclusion Criteria:\n\n1. All patients undergoing Pars Plana Vitrectomy between June 25, 2024 - and December 30, 2024, will be included.\n2. Patients aged 18 years or older\n3. Patients able to give informed consent\n\nExclusion Criteria:\n\n1. Patients with complicated Pars Plana Vitrectomy (choroidal hemorrhage, retrobulbar hemorrhage)\n2. Patients with irregular cornea surface will be excluded (keratoconus, band keratopathy, corneal edema, corneal transplant, cornea scarring)\n3. Patients undergoing combined scleral buckling at time of surgery\n4. Patients with previous glaucoma filtration surgery (ie. trabeculectomy or tube shunt surgery)","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Intraocular pressure is measured regularly at any and all visits with your eye doctor or optometrist.\n\nThe purpose of this study is to compare measurements of eye pressure at the end of the surgery, comparing the ability of a gloved finger or sterile cotton-tipped applicator (\"Q-tip\") to accurately measure intraocular pressure against a standardized instrument designed for this purpose.",[26],"Pars Plana Vitrectomy",[28,29],"intraocular pressure","pars plana vitrectomy","NOT_YET_RECRUITING","2024-11-24",{"date":33,"type":34},"2024-11-27","ACTUAL",{"date":36,"type":20},"2025-03-01",{"date":38,"type":20},"2025-12",{"name":40,"class":41},"Sunnybrook Health Sciences Centre","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100495230","microinvasive-pars-plana-vitrectomy-combined-ilm-peeling-versus-anti-vegf-intravitreal-injection-for-treatment-nave-diabetic-macular-edema-100495230","NCT05728476","Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema","Inclusion Criteria:\n\n* ≥18 years of age\n* Patients and their families fully understand the research and sign the informed consent form\n* Diagnosed with type 1 or 2 diabetes mellitus\n* Hemoglobin A1c (HbA1c) of less than 10% within 3 months\n* Clear media for adequate OCT and optical coherence tomography angiography (OCTA) images\n* Treatment-naïve DME diagnosed clinically\n* Central subfield thickness (CST) of \\>300μm and intra- or subretinal fluid seen on (spectral-domain) SD-OCT\n* Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA between 24 and 73 letters on the day of randomization\n* Treatment within 12 months of DME diagnosis\n* No contraindication of vitrectomy or conbercept intravitreal injection\n\nExclusion Criteria:\n\n* Any previous DME treatment (i.e. anti-VEGF injections, intraocular corticosteroids, macular photocoagulation)\n* Macular edema caused by other disease (i.e. neovascular age-related macular degeneration, retinal vein occlusion, uveitis)\n* Any previous intraocular surgeries (cataract surgery performed at least 3 months before study entry will not be exclusionary)\n* Vision loss caused by other ocular disease (i.e. cataract, proliferative diabetic retinopathy, glaucoma, high myopia)\n* A follow-up duration of less than 12 months\n* Severe dysfunction of the heart, liver, kidney, lung and other organs",{"count":49,"type":20},102,[23],"Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. At present, anti-vascular endothelial growth factor (VEGF) intravitreal injection is the first-line therapy for DME, nevertheless, some patients do not respond well to anti-VEGF agents and often require multiple injections, which increases the psychological and economic burden of patients. Microinvasive pars plana vitrectomy (PPV) has been proven to be safe and effective for refractory DME. However, there are few studies on treatment-naïve DME. The purpose of this study is to explore whether early PPV combined with internal limiting membrane (ILM) peeling can reduce the treatment burden of DME patients, prevent vision loss, and maintain long-term stabilization of diabetic retinopathy.",[53,26,54],"Diabetic Macular Edema","Conbercept","RECRUITING","2024-03-05",{"date":58,"type":34},"2024-03-06",{"date":56,"type":34},{"date":61,"type":20},"2026-09-05",{"name":63,"class":41},"Tianjin Medical University Eye Hospital",1]